Oramed Pharmaceuticals
ORMP
50 hedge funds and large institutions have $8.15M invested in Oramed Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 23 closing their positions.
918% more call options, than puts
Call options by funds: $499K | Put options by funds: $49K
5.03% less ownership
Funds ownership: 10.72% → 5.69% (-5%)
12% less capital invested
Capital invested by funds: $9.3M → $8.15M (-$1.15M)
18% less funds holding
Funds holding: 61 → 50 (-11)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
43% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$528K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$235K |
| 3 |
SRC
Samson Rock Capital
London,
United Kingdom
|
+$118K |
| 4 |
Squarepoint
New York
|
+$110K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.62M |
| 2 |
Two Sigma Investments
New York
|
-$1.43M |
| 3 |
Two Sigma Advisers
New York
|
-$815K |
| 4 |
Morgan Stanley
New York
|
-$771K |
| 5 |
JP Morgan Chase
New York
|
-$386K |
ORMP Hedge Fund Activity: Q2 2023 in Review
50 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2023, worth a combined $8.15M — down 12% from $9.3M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ORMP and 13 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 10 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $528K. The largest seller was BML Capital Management, cutting an estimated $1.62M.
- 50 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2023, down from 61 in Q1 2023.
- Funds reported $8.15M of Oramed Pharmaceuticals stock for Q2 2023, down 12% quarter-over-quarter.
- 13 funds opened new Oramed Pharmaceuticals positions in Q2 2023 and 23 closed out, a net change of -10 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2023 was GSA Capital Partners, an estimated $528K added.
- The largest Oramed Pharmaceuticals seller in Q2 2023 was BML Capital Management, an estimated $1.62M sold.
Based on aggregated 13F filings for Q2 2023.